Isotechnika's independent data monitoring committee conducts review,,,of phase 2b kidney transplant trial ( A247 in three separate pivotalPhase2...)

Isotechnika's independent data monitoring committee conducts review,,,of phase 2b kidney transplant trial

A247 in three separate pivotal Phase2/Phase 3 trials for the treatment of non-infectious uveitis and as a maintenance therapy in uveitis. The Company also successfully completed Phase 1 clinical trials of an additional immunosuppressive compound in its drug pipeline, TAFA93. Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at www.isotechnika.com.

Partnerships with Isotechnika Inc. ----------------------------------

Isotechnika Inc. signed a collaboration agreement with Hoffman La Roche on April 9, 2002, which licensed the worldwide rights to develop and commercialize ISA247 for all transplant indications. On September 30, 2005, Isotechnika Inc. entered into an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders. Isotechnika Inc. and Cellgate Inc. signed an option agreement on April 25, 2006, granting Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis. On May 25, 2006, Isotechnika Inc. signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases.

Forward-Looking Statements --------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
8. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
9. Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis
10. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404

Post Your Comments:

(Date:12/15/2009)... REDWOOD CITY, Calif., Dec. 15 Genomic Health, ... five new studies on its Onco type DX® ... currently use to predict the likelihood of chemotherapy benefit ... These data were presented at the 32nd Annual CTRC-AACR ... 13, 2009, in San Antonio, TX. ,, "The breadth ...

(Date:12/15/2009)... Dec. 15 Arlington Medical Resources (AMR) ... aureus (MRSA) is the most concerning pathogen ... to their treatment of skin and skin structure ... the top factors that influences European physician drug ... Other key factors that drive prescribing include an ...

(Date:12/15/2009)... 15 Amylin Pharmaceuticals, Inc. ... (NYSE: LLY ) and Alkermes, Inc. ... from a head-to-head study comparing exenatide once weekly, ... taken twice daily, in patients with type 2 ... exenatide once weekly experienced a statistically superior reduction ...

Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7 U S Health Costs Will Continue to Cause Financial Pain 56659 1 Nabors Industries Ltd Third Quarter 2009 Earnings Conference Call Invitation 56654 1 Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 13948 1 Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference 13948 2

[0] Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections [0] Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study

... Role in the Pathobiology, of Severe Asthma, Identify Potential New Biomarker for ... ... -, GAITHERSBURG, Md., Nov. 14 MedImmune, Inc. today,announced the ... molecule may play an,important role in determining the mechanisms of severe asthma. ...

... The American Legion,welcomes the findings of an Institute ... be released on Nov 14., "In view of ... health,of military personnel who have served in Iraq and ... timely and important," said Marty,Conatser, national commander of the ...

Other Medicine Technology:The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma 2 The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma 3 The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma 4 The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma 5 American Legion Anticipates Institute of Medicine Report on Gulf War Veterans 2

The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma American Legion Anticipates Institute of Medicine Report on Gulf War Veterans

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... Forecasts to 2015, Competitive Benchmarking, Product ... http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... its latest research "The Future of ...

(Date:12/15/2009)... -- Aon Consulting, the global human capital ... AON ), today announced Lisa Zeitel ... president with the Health & Benefits Practice ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) ... work under the direction of Aon Consulting,s ...

(Date:12/15/2009)... shows a direct correlation between effective workplace health ... culture of health improvement can result in lower ... white paper from The Vitality Group, a provider ... ideal setting for the delivery of health and ... culture of health is a critical component in ...

(Date:12/15/2009)... CLARA, Calif., Dec. 15 Today, ... into Santa Clara County for the first ... Effective immediately, Coastal Healthcare Administrators will be ... by the Physicians Foundation for Medical Care. ... healthcare philosophy, Coastal maintains close working relationships ...

(Date:12/15/2009)... acid synthesis in brain cancer cells may offer a ... glioblastomas that are driven by amplified signaling of the ... study by researchers at UCLA,s Jonsson Comprehensive Cancer Center. ... the formation of new membranes. The fatty acids also ... and may be important for regulating cell signaling, said ...

[0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Aon Consulting Adds Senior Vice President to National Pharmacy Practice [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Coastal Healthcare Administrators Expands Provider Network to Santa Clara County [0] Targeting brain cancer cell metabolism may provide new treatment

... A new study finds that even a little extra income can ... ,"The surprise was at the upper end," said Meredith ... Aug. 17 issue of the New England Journal of Medicine. "We ... and the very rich. To find that the middle class was ...

... of Neurology projects the total cost of ischemic stroke from ... stroke victims playing a major role. ,The study, based ... at the costs of ischemic strokes, which account for the ... ambulances, hospital stays, medications, nursing home care, doctor’s visits and ...

... Shehnai maestro Bismillah Khan was hospitalised here Thursday due to ... 92, had fallen ill about a week ago and was ... ,However, he became very weak prompting the attending ... Varanasi Thursday morning. ,"Bismillah Khan Saheb had been ...

... in a government hospital in Madhya Pradesh allegedly died because his ... tie the umbilical cord.// ,Ram Milan, the father of ... wife to the government hospital in Satna for a safe delivery. ... ,"The nurse on duty demanded Rs.50 for tying the umbilical cord. ...

... agreement between Hewlett Packard and the government in Northern ... prescriptions towards the implementation// of an e-prescriptions service. ... Public Safety has announced that community pharmacies across Northern ... transfer prescriptions over the next two years. ...

... fell ill, five of them seriously, after eating stale food ... many as 44 children of Pratapura Primary School, 60 km ... ,The children complained of stomach ache and ... a day earlier. ,They were taken to ...

Other Medicine News:Health News:The higher the income the lower the disability rates! 2 Health News:Stroke Care Cost To Touch $2.2 trillion by 2050 2

The higher the income the lower the disability rates!Stroke Care Cost To Touch $2.2 trillion by 2050 Shehnai Maestro Bismillah Khan Hospitalised Bribery has Claimed the Life of a Newborn in Madhya Pradesh Paper Prescriptions Give Way to e-Prescriptions in Northern Ireland Students Fell Ill After Eating Stale Food on I-Day

Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides every breath delivery....

Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....

... All-In-One Conserver., ,Offers an average 5:1 increase ... ,Allows the use of a standard cannula. , ... lightweight cylinders offers ambulatory oxygen patients a superior ... by a 2-year warranty. , ...

Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...

Medicine Products:

SEQUOIA OXYMATIC® 311 Electronic Oxygen Conserver 512 Lightweight Pneumatic Conserver OXYMATIC® 411A Electronic Oxygen Conserver LOTUS™ Electronic Oxygen Conserver (with alarm)

( A247 in three separate pivotalPhase2...)Isotechnika's independent data monitoring committee conducts review,,,of phase 2b kidney transplant trial,Health